Last reviewed · How we verify
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
The anti-tumor activity of anti-PD-1 therapy and VEGF inhibitor in TKI-resistant EGFR-mutated non-squamous NSCLC Chinese patients will be investigated in this clinical trial.
Details
| Lead sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
|---|---|
| Phase | PHASE3 |
| Status | COMPLETED |
| Enrolment | 492 |
| Start date | Thu Jul 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Jun 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Non-Squamous Non-Small Cell Lung Cancer
Interventions
- Sintilimab
- IBI305
- Pemetrexed
- Cisplatin
- Placebo1
- Placebo2
Countries
China